Biotron Ltd has released a press release.
Quarterly Cash Flow Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Biotron
- Full Year Statutory Accounts and Preliminary Final Report
- $1.4M R&D Tax Rebate
- Appendix 4C - quarterly
- Quarterly Cashflow Report
- Biotron Compounds Show Activity Against SARS-CoV-2 Virus
Later from Biotron
- Commencement of two pivotal BIT225 clinical trials
- Biotron drug effective against covid-19 in animals
- Quarterly Appendix 4C Cash Flow Report
- BIT225 Effectiveness Against COVID-19 in Animals
- $1.56M R&D Rebate Received
Follow Biotron into a list and get an email when it puts out news.
Follow Biotron